Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10220792 | 0.78 | MAPT (0.42) | KMT2AMEN1MAPTNPSR1ALDH1A1 | |
| SCHEMBL22576229 | 0.78 | ALDH1A1 (0.49) | KMT2AMEN1MAPTNPSR1ALDH1A1 | |
| SCHEMBL24943310 | 0.76 | P2RX3 (0.35) | KMT2AMEN1MAPTNPSR1ALDH1A1 | |
| SCHEMBL24630682 | 0.76 | P2RX3 (0.35) | KMT2AMEN1MAPTNPSR1ALDH1A1 | |
| SCHEMBL26021831 | 0.76 | NUDT1 (0.35) | KMT2AMEN1MAPTNPSR1ALDH1A1 | |
| SCHEMBL23772025 | 0.74 | KMT2A (0.45) | KMT2AMEN1MAPTNPSR1ALDH1A1 | |
| SCHEMBL24943635 | 0.73 | PDGFRB (0.35) | — | |
| SCHEMBL21341302 | 0.72 | NUDT1 (0.32) | NUDT1 | |
| SCHEMBL4754840 | 0.72 | — | — | |
| SCHEMBL21341344 | 0.72 | LMNA (0.42) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257376-A1 | ROCK INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO. LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257376-A1 | ROCK INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO. LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-11130749-B2 | — | — | 2021-09-28 | — | — | US | disclosed |
| US-20190276440-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2019-09-12 | — | — | US | disclosed |
| US-10329282-B2 | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2019-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257376-A1 | ROCK INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | ROCK1, ROCK2, RHOT2 | KMT2A 1244/4885MEN1 371/4885MAPT 2003/4885 |
| US-11130749-B2 | — | ROCK1, RHOA, ROCK2 | KMT2A 4097/4885MEN1 1552/4885MAPT 253/4885 |
| US-10329282-B2 | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof | ROCK1, RHOA, ROCK2 | KMT2A 3969/4885MEN1 1946/4885MAPT 432/4885 |
| US-20190276440-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | ROCK1, ROCK2, RHOA | KMT2A 3464/4885MEN1 1685/4885MAPT 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.